ArticleAsian Pacific journal of cancer prevention : APJCP2025
Molecular and Serological Detection of Human Parvovirus B19 in a Sample of Iraqi Patients with Acute Lymphoid Leukemia in Relation to Hematological Parameters.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Parvovirus B19, Somatic Gene Mutations, and Hematologic Malignancy Subtypes: An Analytical Study.Asian Pacific journal of cancer prevention : APJCP · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute Lymphoblastic Leukemia (ALL) is a common childhood blood cancer. Human Parvovirus B19 (PV-B19) mainly replicates in bone marrow erythroblasts and can persist long after initial infection. ALL patients frequently exhibit PV-B19 viremia, arising from either viral reactivation or coincidental infection amid acute leukemia. Aims of the Study: This study aimed to determine the prevalence PV-B19 infection in ALL patients, investigate its association with hematological parameters at presentation, and monitor these parameters and disease progression in relation to PV-B19 infection. PATIENTS AND
methodsThis case-control study included 30 newly diagnosed acute lymphoblastic leukemia patients and 30 healthy blood donors as controls. Patients' data were collected through interviews or records. Plasma levels of anti-PV-B19 IgG and IgM antibodies were assessed by enzyme-linked immunosorbent assay (ELISA), and viral DNA quantification was performed using quantitative polymerase chain reaction (qPCR).
resultsThe IgG and IgM prevalence in patients was 36.67% and 3.33%, respectively, compared to 33.33% and 0% in controls. The molecular assay revealed 63.33% of patients were PV-B19 DNA positive, significantly higher than the 6.67% in controls. Patients had a significantly higher mean log10 viral load (5.17±1.39 copies/ml) than controls (2.64± 0.28 copies/ml) (P= 0.019). PV-B19 had no significant association with hematological parameters before chemotherapy; however, after chemotherapy, viral infection was significantly associated with reduced chemotherapy response and increased blood transfusion rate.
conclusionsPV-B19 infection seems to have more pronounce role in ALL after treatment initiation, where it associates with increased rate of blood transfusion and reduced response to chemotherapy. Therefore, PV-B19 should be considered in acute leukemia patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.